Acasti Pharma Announces Fiscal 2013 Results and Provides Update on Status of Clinical Trials

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LAVAL, Quebec, May 22, 2013 (GLOBE NEWSWIRE) -- Acasti Pharma ("Acasti" or the "Corporation") (Nasdaq:ACST) (TSX-V:APO), a Neptune Technologies & Bioressources Inc.'s ("Neptune") subsidiary, announces its consolidated financial results for the fourth quarter and fiscal year ended February 28, 2013 and provides an update on the status of its Phase II clinical trials.

Help employers find you! Check out all the jobs and post your resume.

Back to news